Future preclinical studies in large animal models will be needed to address optimal chemistry, application regime, and pharmaco-kinetics of AON in vivo for optimal rescue of DCM-associated truncating mutations in TTN. The gene discussed is TTN; the disease is familial dilated cardiomyopathy.